Krka d. d Full Year 2023 Earnings: EPS: €10.14 (vs €11.69 in FY 2022)
Krka d. d (LJSE:KRKG) Full Year 2023 Results
Key Financial Results
- Revenue: €1.81b (up 5.2% from FY 2022).
- Net income: €313.9m (down 14% from FY 2022).
- Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses.
- EPS: €10.14 (down from €11.69 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Krka d. d Earnings Insights
Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in Europe.
The company's shares are up 1.2% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Krka d. d, and understanding this should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Krka d. d might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LJSE:KRKG
Krka d. d
Develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
Flawless balance sheet with solid track record and pays a dividend.